{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:05:52Z","timestamp":1790820352110,"version":"4.1.0"},"reference-count":30,"publisher":"Cambridge University Press (CUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Cardiol Young"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"S1047951126113729_as1\">\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Anthracyclines are indispensable in paediatric oncology but are associated with well-recognised dose-dependent cardiotoxicity that may result in progressive cardiomyopathy and late heart failure. Dexrazoxane has emerged as a potential primary cardioprotective strategy; however, concerns regarding safety, secondary malignancies, and possible interference with antitumour efficacy have historically limited its widespread adoption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S1047951126113729_as2\">\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To critically review current evidence regarding the efficacy, safety, and clinical applicability of dexrazoxane in children receiving anthracycline-based chemotherapy, including region-specific implications for Latin America.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S1047951126113729_as3\">\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Narrative review of randomised controlled trials, observational studies, systematic reviews, meta-analyses, and international guideline statements evaluating cardiac outcomes, survival, toxicity profiles, and second primary malignancy risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S1047951126113729_as4\">\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Dexrazoxane consistently demonstrates cardioprotective effects, including reduced biomarkers of myocardial injury and improved preservation of left ventricular systolic function, particularly among patients exposed to higher cumulative anthracycline doses. Available data indicate no significant adverse impact on relapse rates, event-free survival, or overall survival. Although early studies raised concerns about increased second primary malignancies, subsequent investigations have yielded inconsistent results, leaving residual uncertainty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S1047951126113729_as5\">\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Dexrazoxane represents an effective cardioprotective strategy in selected high-risk paediatric patients. A risk-adapted approach balancing cardioprotection, oncologic safety, and healthcare resources is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1017\/s1047951126113729","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T06:45:12Z","timestamp":1782801912000},"page":"1340-1343","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":0,"title":["Dexrazoxane in children receiving anthracyclines: efficacy, safety, and region-specific considerations for Latin America"],"prefix":"10.1017","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0200-5310","authenticated-orcid":false,"given":"Alejandro","family":"Goldsman","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05te51w08","id-type":"ROR","asserted-by":"publisher"}],"name":"El Hospital de Ni\u00f1os Ricardo Gutierrez"},{"id":[{"id":"https:\/\/ror.org\/04czhsq43","id-type":"ROR","asserted-by":"publisher"}],"name":"CEMIC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica Victoria","family":"Stelmaszewski","sequence":"additional","affiliation":[{"name":"Hospital de Pediatr\u00eda Prof Dr Juan P Garrahan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Gonzalez Ortiz","sequence":"additional","affiliation":[{"name":"Asociaci\u00f3n Medica del Centro Medico ABC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena del Pilar","family":"Prada Casilimas","sequence":"additional","affiliation":[{"name":"Clinica Imbanaco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Arevalo Leal","sequence":"additional","affiliation":[{"name":"Hospital Pediatrico La Misericordia"},{"name":"Hospital Universitario Mayor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Biancolini","sequence":"additional","affiliation":[{"name":"Hospital General de Ni\u00f1os Pedro de Elizalde"},{"name":"Sanatorio Sagrado Coraz\u00f3n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7131-5662","authenticated-orcid":false,"given":"Angela","family":"Sardella","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05te51w08","id-type":"ROR","asserted-by":"publisher"}],"name":"El Hospital de Ni\u00f1os Ricardo Gutierrez"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Maza Caneva","sequence":"additional","affiliation":[{"name":"Organizaci\u00f3n Cl\u00ednica General del Norte"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3862-7672","authenticated-orcid":false,"given":"Ricardo","family":"Pignatelli","sequence":"additional","affiliation":[{"name":"Texas Children\u2019s Hospital"},{"name":"Baylor College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"S1047951126113729_ref19","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25043"},{"key":"S1047951126113729_ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.3879"},{"key":"S1047951126113729_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(22)00239-5"},{"key":"S1047951126113729_ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035153"},{"key":"S1047951126113729_ref10","unstructured":"10. EMA. European Medicines Agency. Assessment report. Dexrazoxane-containing medicinal products (EMEA\/H\/A-31\/1275). 2011."},{"key":"S1047951126113729_ref15","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25753"},{"key":"S1047951126113729_ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.6888"},{"key":"S1047951126113729_ref7","first-page":"85","article-title":"Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits","volume":"31","author":"Herman","year":"1981","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"S1047951126113729_ref11","unstructured":"11. EMA. European Medicines Agency. Questions and answers on Cardioxane (dexrazoxane: powder for solution for injection: 500 mg). Outcome of a procedure under Article 13 of Regulation (EC) No 1234\/2008. 2017."},{"key":"S1047951126113729_ref30","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.51062"},{"key":"S1047951126113729_ref14","doi-asserted-by":"publisher","DOI":"10.1179\/1973947812Y.0000000038"},{"key":"S1047951126113729_ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510795"},{"key":"S1047951126113729_ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.3920"},{"key":"S1047951126113729_ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4473"},{"key":"S1047951126113729_ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8851"},{"key":"S1047951126113729_ref1","volume-title":"SEER Cancer Statistics Review, 1975-2018","author":"Howlader","year":"2021"},{"key":"S1047951126113729_ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.1373"},{"key":"S1047951126113729_ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e3182a88099"},{"key":"S1047951126113729_ref27","first-page":"1005","article-title":"Dexrazoxane. A review of its use for cardioprotection during anthracycline chemotherapy","volume":"65","author":"Cvetkovic","year":"2005","journal-title":"Drugs"},{"key":"S1047951126113729_ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30133-4"},{"key":"S1047951126113729_ref25","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31833"},{"key":"S1047951126113729_ref28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003917.pub2"},{"key":"S1047951126113729_ref21","first-page":"CD014638","article-title":"Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines","volume":"9","author":"Baat","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"S1047951126113729_ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2022.100155"},{"key":"S1047951126113729_ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02423"},{"key":"S1047951126113729_ref29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.10513"},{"key":"S1047951126113729_ref23","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv357"},{"key":"S1047951126113729_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30537-0"},{"key":"S1047951126113729_ref26","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25206"},{"key":"S1047951126113729_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.03.022"}],"container-title":["Cardiology in the Young"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1047951126113729","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:45:42Z","timestamp":1790819142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1047951126113729\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1047951126113729"],"URL":"https:\/\/doi.org\/10.1017\/s1047951126113729","relation":{},"ISSN":["1047-9511","1467-1107"],"issn-type":[{"value":"1047-9511","type":"print"},{"value":"1467-1107","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"\u00a9 The Author(s), 2026. Published by Cambridge University Press","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}